ArticleJournal of nanobiotechnology2026
Effects and mechanism of carrier-free self-assembled nanoparticles of natural products in attenuating pulmonary edema.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPulmonary edema, a life-threatening condition in acute lung injury/acute respiratory distress syndrome (ALI/ARDS), is driven by dysregulated inflammation, barrier disruption, and alveolar fluid accumulation. Effective therapies that simultaneously target these multiple pathological processes with high lung specificity are urgently needed.
resultsWe engineered carrier-free, self-assembled nanoparticles from the natural products magnolol (Mag) and atractylenolide I (ATI) at an optimal 4:1 molar ratio. The Mag-ATI nanoparticles (MA NPs) exhibited an average hydrodynamic diameter of approximately 220.2 nm, excellent colloidal stability, and a pH-responsive release profile favorable for the acidic pulmonary microenvironment. The drug loading was 81.7 ± 0.356% for Mag and 18.2 ± 0.129% for ATI, encapsulation efficiency exceeded 97% for both. In a murine lipopolysaccharide (LPS)-induced ALI model, MA NPs potently ameliorated pulmonary edema, outperforming individual drugs or their physical mixture. Biodistribution studies confirmed the MA NPs' efficient lung accumulation, with a fluorescence intensity 3.6-5.9 times higher than in other organs, and specific targeting to alveolar epithelial cells. Mechanistically, Mag inhibited TRPV4-mediated Ca
conclusionThis study presents a novel, carrier-free nanotherapeutic platform that integrates the efficacy-enhancing rationale of traditional herbal medicine with advanced nanoassembly. By enabling coordinated modulation of inflammation, barrier function, and fluid homeostasis, MA NPs offer a potent, targeted, and translational strategy for the treatment of ALI/ARDS.
Indexed as
Identifiers
42421105What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.